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Background: Autism spectrum disorders (ASDs) are relatively common neurodevelopmental conditions whose
biological basis has been incompletely determined. Several biochemical markers have been associated with ASDs,
but there is still no laboratory test for these conditions.
Methods: We analyzed the metabolic profile of lymphoblastoid cell lines from 137 patients with
neurodevelopmental disorders with or without ASDs and 78 normal individuals, using Biolog Phenotype
MicroArrays.
Results: Metabolic profiling of lymphoblastoid cells revealed that the 87 patients with ASD as a clinical feature, as
compared to the 78 controls, exhibited on average reduced generation of NADH when tryptophan was the sole
energy source. The results correlated with the behavioral traits associated with either syndromal or non-syndromal
autism, independent of the genetic background of the individual. The low level of NADH generation in the
presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability,
schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits.
Analysis of a previous small gene expression study found abnormal levels for some genes involved in tryptophan
metabolic pathways in 10 patients.
Conclusions: Tryptophan is a precursor of important compounds, such as serotonin, quinolinic acid, and kynurenic
acid, which are involved in neurodevelopment and synaptogenesis. In addition, quinolinic acid is the structural
precursor of NAD+, a critical energy carrier in mitochondria. Also, the serotonin branch of the tryptophan metabolic
pathway generates NADH. Lastly, the levels of quinolinic and kynurenic acid are strongly influenced by the activity
of the immune system. Therefore, decreased tryptophan metabolism may alter brain development, neuroimmune
activity and mitochondrial function. Our finding of decreased tryptophan metabolism appears to provide a unifying
biochemical basis for ASDs and perhaps an initial step in the development of a diagnostic assay for ASDs.
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Autism spectrum disorders (ASDs) constitute a heteroge-
neous group of neurodevelopmental conditions character-
ized by three core signs: impairment of social interactions,
communication issues, and repetitive behaviors. The preva-
lence of ASDs is approximately 1% in the US population
aged <8 years [1] and the conditions have a tremendous* Correspondence: ceschwartz@ggc.org
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reproduction in any medium, provided the orimpact on society and families as affected individuals
utilize a wide range of services and considerable resources
[2]. Currently, ASDs are diagnosed solely by analysis of
the complex behavioral phenotype and such diagnosis is
typically not performed before the age of 3 years, even if
recent progress has allowed diagnosis at an earlier age [3].
A strong genetic predisposition for ASDs has been in-
ferred from a higher concordance in identical twins as
compared to fraternal twins, a significant sib recurrence
risk, and the identification of a predisposing genetic event
in 15% to 30% of ASD children [4,5]. Nevertheless, ASDs
exhibit a remarkable genetic heterogeneity and a pathogenicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is difficult to postulate.
The investigation for the molecular bases of these disor-
ders has highlighted numerous metabolic abnormalities in
ASD patients and several biochemical markers have been
associated with autistic traits (hyperserotoninemia [6],
urinary catabolites of sulfur and amino acid metabolism
[7], and oxidative metabolism biomarkers [8]). However,
there are still no laboratory tests that offer a reliable con-
firmation for the clinical diagnosis, or provide for efficient
screening of individuals presenting with behavioral fea-
tures suggestive of ASDs.
Methods
Patient and control cell lines
We analyzed 87 ASD patients, 80 patients with non-
syndromal ASDs and seven patients with syndromal ASDs.
Overall, 74 ASD patients were male and 13 were female, a
5.69:1 ratio. The age range was 2.5 to 34.25 years at the
time the blood sample was obtained. The non-syndromal
patients were part of the South Carolina Autism Project
(SCAP) and were diagnosed with autistic disorder based
on evaluation using the Autism Diagnostic Interview-
Revised (ADI-R) and according to the Diagnostic and
Statistical Manual of Mental Disorders (DSM) IV-Revised
criteria [9]. Genetic tests excluded major chromosomal
abnormalities, Fragile X syndrome, Rett syndrome (by
testing the MECP2 gene), and abnormalities in plasma
amino acid levels. The seven syndromal patients were
diagnosed with ASDs based on evaluation using the ADI-
R and the Autism Diagnostic Observation Schedule
(ADOS), according to the DSM IV-Revised criteria. Two
cell lines from patients with Fragile X syndrome were pro-
vided from the Catholic University of Sacred Heart, Rome,
Italy. We also analyzed 35 patients with 15 different intel-
lectual disability (ID) conditions who were known to have
mutations in ID-associated genes, and 10 patients with
schizophrenia, provided by the Ste-Justine Hospital
Research Center, University of Montreal, Canada. We
compared these various patients with 78 controls, who
were matched by age (range, 4.17-53.5 years at blood
sampling), sex (66 males and 12 females, ratio 5.2),
and geographic area.
Informed consent was approved by the Self Regional
Healthcare Institutional Review Board (IRB) for Human
Research and was reviewed and signed by all the partici-
pants evaluated and/or their legal guardian. The IRB ap-
proved the use of the samples in the studies reported in
this paper.
Cell lines were obtained by immortalization of lym-
phocytes from blood samples using Epstein-Barr virus.
The lymphoblastoid cell lines were harvested in Sigma
RPMI-1640 with 75 mL fetal bovine serum from Atlanta
Biological (Lawrenceville, GA,USA) and 5mLL-Glutamineand 5 mL antibiotic/antimycotic from Sigma-Aldrich (St.
Louis,MO,USA).
Biolog metabolic arrays
The Phenotype MicroArray (PM) developed by Biolog
(Hayward, CA, USA) is designed to provide an unbiased
scan of the activity of cellular metabolic pathways in-
volved in the rate of production of NADH (nicotinamide
adenine dinucleotide, reduced form). The methodology
employs microplates with diverse carbon energy sources
(plate PM-M1), as well as amino acids, both alone and
as dipeptides (plates PM-M2 to M4). Each well contains
a single chemical as the sole energy source and produc-
tion of NADH per well is monitored using a colorimetric
redox dye chemistry [10]. PM-M plates were incubated
with 20,000 lymphoblastoid cells per well in a volume of
50 μL. The cells were incubated for 48 h at 37°C in 5%
CO2, using the modified Biolog IF-M1 medium. This
medium was prepared by adding the following to 100
mL of Biolog IF-M1: 1.1 mL of 100× penicillin/strepto-
mycin solution, 0.16 mL of 200 mM Glutamine (final
concentration 0.3 mM), and 5.3 mL of fetal bovine
serum (final concentration 5%). During the 48-h incuba-
tion, the only energy source the cells had was the chem-
ical in the well. After this first incubation, Biolog Redox
Dye Mix MB was added (10 μL/well) and the plates were
incubated under the same conditions for an additional 24
h, during which time the cells metabolize the sole carbon
source in the well. As the cells metabolize the carbon
source, tetrazolium dye in the media is reduced, produ-
cing a purple color according to the amount of NADH
generated. For further details on the Biolog Phenotype
MicroArray see Bochner et al. [10] and Putluri et al. [11].
At the end of the 24 h incubation, the plates were ana-
lyzed utilizing a microplate reader with readings at 590
and 750 nm. The first value (A590) indicated the highest
absorbance peak of the redox dye and the second value
(A750) gave a measure of the background noise. The rela-
tive absorbance (A590-750) was calculated per well.
For the last experiment of 50 ASD patients versus 50
controls, we used the customized Biolog plates described
below following the same protocol described above.
Customized metabolic plates
Customized plates were designed by Biolog for the 50
ASD patients versus 50 controls experiment. The wells
contained a positive control (α-D-glucose), a negative
control (empty well), L-tryptophan, and the five most
informative tryptophan dipeptides (Trp-Gly, Trp-Lys,
Trp-Ala, Trp-Arg, and Trp-Leu).
Human gene expression microarrays
The Agilent Whole Human Genome Oligo Microarray,
containing over 40,000 human genes and transcripts [12],
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from 10 patients with ASDs and 10 controls. Two
independent microarray experiments were performed for
each sample. To maximize the contrast between samples,
we implemented a loop experimental design [13] with
dye swap. Total RNA was isolated using the Agilent
Total RNA Isolation Mini Kit (Agilent Technologies,
Wilmington, DE, USA). RNA samples were labeled with
Cy3 or Cy5 fluorescent dye and hybridized for 17 h,
and microarray slides were washed and scanned with
Agilent G2505B microarray scanner. Image processing
and fluorescence intensity were interpreted and ana-
lyzed by Agilent Feature Extraction (version 9.1).
Data processing and statistical analysis
Phenotype MicroArray (PM) analysis
For PM data, the absorbance readings were transformed
to a logarithmic scale. We assumed that as a group, pa-
tients with ASDs share a similar metabolic profile. At the
first stage, as an exploratory approach, our goal was to
identify the wells in which ASD patients were significantly
different from the controls. We utilized a popular statis-
tical program, Significance Analysis of Microarray (SAM)
[14], which implements a modified t test by assigning a
score to each observation on the basis of change and uti-
lizes permutations to estimate the percentage of observa-
tions identified by chance using a false discovery rate
(FDR). FDR maintains a balance between the number of
false positives [15] and true positives and is equivalent to
the family-wise error but with a gain in power. We used
FDR at 1% as the selection threshold. At the second stage,
after selecting most of the tryptophan-containing wells as
the main focus, a t test with Bonferroni correction was
used for determination of statistical significance.
Feature selection
In order to determine whether each tryptophan dipeptide
possesses the same statistical power in distinguishing
patients from controls, we utilized 10 feature selection
methods. Since each feature selection method contains
a bias, we adopted a ‘voting’ strategy to look for
‘features’ (that is, tryptophan substrates) selected by
the majority of the algorithms. We utilized 10 fea-
ture selection methods (CfsSubsetEval, ChiSquared,
FilteredAttribute, FilteredSubset, GainRatioAttribute,
InfoGainAttribute, OneRAttribute, ReliefFAttribute,
SVMAttribute, SymmetricalUncertAttribute) in the Weka
package [16] and had each method rank and report the
best top five discriminators.
Expression microarray analysis
For the Agilent expression arrays, data normalization and
statistical analysis were performed as in the reference [17].Results
Identification of reduced tryptophan metabolism in the
ASD cells
We initiated an investigation of the metabolic profile of
lymphoblastoid cell lines from patients with different
neurobehavioral disorders and normal individuals, utiliz-
ing Biolog Phenotype MicroArray plates to see if patients
with specific disorders had a characteristic profile. The
assay, as carried out, analyzes the NADH generation in
the presence of each substrate by measuring the redox
color change of a tetrazolium dye after 24 h of incubation.
We first tested the ability of lymphoblastoid cells to
utilize the 367 substrates in the PM plates in 18 controls
and 55 patients. Seventeen of these patients were affected
with ASDs and 38 had 15 different intellectual disability
(ID) conditions and known pathogenic mutations in
specific ID-associated genes. Of the 17 ASD patients, 10
had non-syndromal autistic disorder with known genetic
alterations: two of these patients were monozygotic male
twins with a chromosome 3p26.2 deletion, not involving
any reported gene, one had a chromosome 2p21 dupli-
cation and a chromosome 20p21.1 deletion, three had
SHANK3 mutations, two had NLGN4 mutations, and one
had a balanced translocation involving chromosomes 14
and 15. The remaining seven cell lines were from patients
with syndromal autism: four cases had Fragile X syn-
drome, autistic features and full methylation at the
FRAXA locus; two cases had Rett syndrome and MECP2
mutations; one case had a ZNF711 mutation, X-linked in-
tellectual disability and clinical findings consistent with
ASDs (see Additional file 1: Table S1 for more detailed
description).
The analysis of the Biolog PM plate data was conducted
in a blind fashion so that one of us (CFC) was ignorant of
the clinical information connected to each patient. The
analysis of the assay data revealed significant differences
in the utilization of multiple substrates as an energy
source for most patient cell lines when they were com-
pared to the controls. However, once the clinical infor-
mation was attached to the data, if an ASD was present,
it was noted that the 25 substrates with the greatest
statistical significance (P value ≤0.001) contained a form
of tryptophan, and all 27 wells containing tryptophan
had P values ≤0.05 (Additional file 2: Table S2). This
collective finding was independent of whether trypto-
phan was alone in the well or in the first or second pos-
ition of a dipeptide. These observations suggested that
lymphoblastoid cell lines from either syndromal or non-
syndromal ASD patients exhibit reduced tryptophan
metabolism as compared to normal individuals. Among
the top 50 wells with a significant difference between
patients without ASDs and controls, none contained
tryptophan (Additional file 3: Table S3). Out of 222 sub-
strates that met the minimal statistical threshold for
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tophan (Lys-Trp and Pro-Trp) for patients without
ASDs. The results suggest that tryptophan metabol-
ism in lymphoblast cells from non-ASD patients with
neurodevelopmental disorders is not significantly dif-
ferent as compared to normal individuals.
It is noteworthy that some of these patients were af-
fected by conditions that sometimes may present with
autistic traits: (1) two cell lines were from patients with
Angelman syndrome, a condition often considered in
the differential diagnosis of Rett syndrome, who did not
meet criteria for ASDs; and (2) a patient with a ZNF711
mutation who did not exhibit ASD features.
In order to evaluate the specificity of our finding with
regard to the behavioral phenotype associated with ASDs,
we tested 10 patients with schizophrenia, a condition that
shares some features with ASDs. We did not detect sig-
nificant abnormalities in tryptophan metabolism, as com-
pared to controls (data not shown).
In summary, these data suggested that the reduced tryp-
tophan metabolism: (1) was a prominent feature common
for the 17 ASD patient cell lines tested, as a group, inde-
pendent of whether the autistic traits were the sole clinical
findings in the patients or whether they were accompanied
by other signs in a syndromal condition; (2) was extremely
rare in patients with similar conditions but without fea-
tures consistent with ASDs; and (3) was not observed in
other neurodevelopmental conditions.Validation studies and feature selection
In order to replicate our initial results, we tested an
additional 20 patients with autistic disorders, according
to the DSM IV-Revised criteria, 10 new controls and 10
of the previously tested controls randomly selected.
Thirteen of the 20 ASD patients had genetic abnormal-
ities: seven patients had the MET rs1858830 C/C geno-
type, four had chromosomal rearrangements found by
array-CGH analysis, one had a balanced translocation
involving chromosomes 13 and 15, and one had a muta-
tion in the OCRL1 gene. To focus our analysis on tryp-
tophan metabolism, we utilized only the PM-M4 plate,
which contains the 12 wells with tryptophan as the first
amino acid in various dipeptides. The PM-M4 plate also
contains 17 wells with tyrosine, an amino acid that
shares some common pathways with tryptophan and
whose utilization was significantly reduced in 19/27
wells (70.4%) in our previous cohort. The Biolog results
in these ASD cell lines, on average, indicated that the
tryptophan metabolism was reduced when compared to
the controls (Figure 1 and Additional file 4: Table S4),
which was consistent with our findings for the previ-
ously tested 17 ASD cell lines. No significant changes
were detected for the wells containing tyrosine, exceptfor the one with the tryptophan-tyrosine dipeptide
(Additional file 4: Table S4).
We investigated whether each tryptophan dipeptide
possesses the same statistical power in distinguishing
patients from controls. Ten feature selection methods
were utilized to analyze the data obtained from the
experiments of 20 controls vs. 20 patients. The ana-
lysis revealed that the top tryptophan dipeptides in
order of informative power were: tryptophan-glycine
(Trp-Gly), tryptophan-lysine (Trp-Lys), tryptophan-
alanine (Trp-Ala), tryptophan-arginine (Trp-Arg), and
tryptophan-leucine (Trp-Leu).
The results allowed us to design a customized 96-well
plate with 12 columns of eight wells. These customized
plates were used to test lymphoblastoid cell lines from
new, unrelated cohorts of 50 ASD patients and 50 con-
trols. This experiment, using five tryptophan dipeptides
along with a positive control (α-D-glucose), a negative
control (empty well), and L-tryptophan, replicated our
previous observations of reduced tryptophan metabolism
in lymphoblastoid cell lines from patients with ASDs
(Figure 2). We also noticed that the positive control well
containing glucose showed a difference between controls
and patients with ASDs, even if not as significant as the
one observed in the wells containing tryptophan. This
observation suggested that there might exist some fun-
damental differences in the general energetic metabolism
between ASD cases and controls, which were not ob-
served in our previous data. To determine if the contri-
bution of this possible general effect of energy utilization
affected our results, we re-analyzed the data by ‘normal-
izing’ the tryptophan values with the positive control
well. For each individual we have tested, we subtracted
the value of each well containing tryptophan from the
corresponding value of the well containing glucose. The
result of this ‘normalization’ was that data still supported
the previous observation that the lymphoblastoid cell
lines of the patients with ASDs, on average, utilize tryp-
tophan less effectively than those of controls (data not
shown).
Since the experiment exploring the detected five trypto-
phan dipeptides utilized a larger cohort and more diverse
group of samples, we tested whether age was a co-factor
for the difference observed. A Spearman correlation ana-
lysis failed to find any age-related effect on the tryptophan
utilization either in the patients with ASDs or in the con-
trols (results not shown).
Gene expression in the tryptophan metabolic pathway
It is reasonable to hypothesize that the observed reduc-
tion of tryptophan metabolism in ASD cell lines may
stem from abnormal functions along tryptophan meta-
bolic pathways in the cells. We therefore mined data
generated from a small gene expression profiling study
Figure 1 Histogram of energy metabolism in the ASD cells vs. control cells. The bar height of the histogram indicates the mean of
measurements of 20 cell lines for each group; vertical bars are standard errors of the means. Star* symbol denotes level of statistical significance
determined by a t test: **P <0.01; *P <0.05. The substrates were ordered according to their individual P values with the lowest on the left.
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The study employed the Agilent Whole Human Genome
Oligo Microarrays and RNA extracted from the initial
10 ASD cell lines and 10 controls (Figure 3 and online).
The data indicated that two genes, SLC7A5 and SLC7A8,
coding for tryptophan transporter subunits, expressed
in both blood and brain, had reduced expression in all
patients (Figures 3 and 4). The mitochondrial isoform
of tryptophanyl tRNA synthetase (WARS2) had signifi-
cantly reduced expression (P <0.001) in a majority (6/10) of
the ASD cell lines while the cytoplasmic isoform (WARS)
showed no difference in expression levels (Figures 3 and 4,
Additional file 5: Table S5).Figure 2 Histogram of energy metabolism in the ASD cells vs. contro
measurements of 50 cell lines for each group; vertical bars are standard err
significance determined by a t test: ***P <0.001. The substrates were ordereThe two main pathways of tryptophan metabolism
lead to the synthesis of serotonin and kynurenine [18].
Tryptophan hydroxylase is the rate-limiting enzyme in
the biosynthesis of serotonin and the gene encoding the
isoform 2 of this enzyme (TPH2) showed significantly
reduced expression levels (Figures 3 and 4, Additional
file 5: Table S5). Also, several genes coding for enzymes
involved in the kynurenine pathway showed significant
differences (P <0.05) between ASD cell lines and con-
trols. The expression levels of AADAT, HAAO, and
MAOA were reduced in patients with ASDs, while QPRT
showed a non-significant trend towards over-expression
(Figure 3 and Additional file 5: Table S5).l cells. The bar height of the histogram indicates the mean of
ors of the means. Star symbol (*) denotes level of statistical
d according to their individual P values with the lowest on the left.
Figure 3 Histogram of gene expression of selected genes in tryptophan metabolic pathway in the ASD cells vs. control cells. The bar
height of the histogram indicates the mean of measurements of 10 cell lines for the controls and 10 cell lines of patients with ASDs. Vertical bars
are standard errors of the means. Symbol denotes level of statistical significance determined by a t test: *P <0.05; **P <0.01. ns, non-significant.
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significant expression differences between ASD patients
and controls, and each patient exhibited a different pro-
file for the group of genes examined. However, each of
the 10 ASD patients showed significant differences
(P <0.05) from controls in the expression levels of at
least 9/15 genes involved in tryptophan metabolism
(Additional file 5: Table S5).
Discussion
Our findings show an abnormal utilization of trypto-
phan as energy source in cells from patients with
ASDs, suggesting impaired tryptophan metabolism.
Our analysis consisted of three independent sets of
experiments in which we measured NADH production
in 87 lymphoblastoid cells derived from ASD patients
as compared to 78 controls. The difference between
the case–control populations was statistically signifi-
cant in each of these experiments. The statistical ana-
lysis was performed in a blind fashion with regard to
the presence of ASDs in the patients. The results cor-
related with the behavioral traits associated with either
syndromal or non-syndromal autism, independent of
the genetic background of the individual. The low
level of NADH generation in the presence of trypto-
phan was not observed in cell lines from patients with
intellectual disability without ASD or schizophrenia,
or in conditions showing several similarities with
syndromal ASDs except for the behavioral traits.
Metabolism of tryptophan via the serotonin synthesis
pathway leads to production of NADH, while metabolism
via the kynurenine-quinolinic acid pathway leads to thesynthesis of NAD+, the precursor of NADH (Figure 4).
The decreased level of NADH generation in the presence
of tryptophan may reflect less utilization of tryptophan
resulting from downregulation of metabolic reactions
along either of these pathways.
Analysis of microarray expression data previously
collected on the initial 10 ASD patient cell lines and
10 controls found reduced levels of some genes in-
volved in the serotonin and kynurenine pathways in
ASD patients. No two patients exhibited the same
expression profile. The enzyme responsible for the
conversion of quinolinic acid to nicotinate D-
ribonucleotide (quinolinate phosphoribosyltransferase)
showed a trend towards increased expression, although
this was statistically significant in only seven out of the 10
cell lines analyzed, when each cell line was individually
compared to the control group using the Mann–Whitney
one sample test (Additional file 5: Table S5). This enzyme
links the tryptophan-kynurenine pathway to NAD+ bio-
synthesis (Figure 4) and is produced by a gene (QPRT)
mapping to 16p11.2. Deletions and duplications of this
region have been frequently associated with ASDs,
suggesting that abnormal dosage of the genes in 16p11.2
may be responsible for autism features [19].
Pyridoxine and its metabolite, pyridoxal phosphate, play
a critical role as co-factors in both the serotonin and
kynurenine pathways, so their deficiency may affect tryp-
tophan metabolism. Unfortunately, the PM plates do not
contain any compound closely related to pyridoxine. Add-
itionally, our limited microarray data for the enzymes in-
volved in pyridoxine/pyridoxal phosphate metabolism
(PHOSPHO2, PDX, PNPO) did not show significant
Figure 4 Tryptophan pathways. The figure illustrates the main intracellular pathways involving tryptophan. Genes with reduced expression in
our microarray dataset are in blue, genes with increased expression are in red. Genes with statistically significant reduction of expression are
underlined. Reactions generating NADH are indicated in the top section of the figure. FAD, flavin adenine dinucleotide.
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patients.
Our findings support a possible mitochondrial dys-
function as a result of impaired tryptophan metabol-
ism in cells from patients with ASDs [20] and several
biochemical mechanisms could be responsible. NADH
is a critical energy carrier for the electron transport chain
and tryptophan is the main precursor of the kynurenine-
quinolinic acid pathway that leads to NAD+ synthesis.
Furthermore, the expression microarray data from a
previous study revealed selective under-expression of
the mitochondrial isoform of tryptophanyl tRNA syn-
thetase (WARS2) in 6/10 cell lines from ASD patients,
and normal expression levels for the cytoplasmic iso-
form (WARS1). Considering the expression of tRNA
genes is sensitive to the availability of the corresponding
amino acid, it is possible the tryptophan levels in mito-
chondria are lower in ASD patients than controls
(Figure 4).In the brain, mitochondrial dysfunction has an effect
on neuronal development and morphology, neurite
overgrowth, and synaptic plasticity [20-22]. There ap-
pears to be a close link between mitochondrial dysfunc-
tion and synaptic abnormalities, which are considered
one of the main pathogenic events associated with ASDs
[5,23]. Five of the first 10 ASD cases had a mutation in
genes involved in glutamatergic synapses (SHANK3 and
NLGN4). Also, some of the pathways involved in regula-
tion of synaptic protein expression [24] are also in-
volved in the expression of protein destined for the
mitochondria.
The biochemical pathway that leads to NAD+ syn-
thesis, beginning with tryptophan, is the kynurenine
pathway (Figure 4) which has two major final prod-
ucts: quinolinic acid (metabolized to nicotinamide and
NAD+), and kynurenic acid [18]. Some of the most
frequently reported neuroanatomical findings in ASD
brains are increased brain size and relatively increased
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possible that impairment of the quinolinic-kynurenic bal-
ance may have consequences on the programmed ‘prun-
ing’ process and lead to an excess of white matter.
Microglial cells are considered to be responsible for keep-
ing the proper balance between quinolinic and kynurenic
acid, since they are able to secrete both compounds. The
expression of those molecules is strongly influenced by
the activity of the immune system. Particularly, nitric
oxide (NO) plays a critical role in the interaction between
inflammation and neuronal circuits and causes mitochon-
drial dysfunction. It is important to note that elevated NO
levels have been reported in ASD patients [27,28].
Although approximately 99% of the dietary tryptophan
intake is metabolized via the kynurenine pathway [18],
tryptophan is also the main precursor for both serotonin
and melatonin (Figure 4). Melatonin plays a critical role in
the regulation of the circadian rhythm, and anomalies of
this rhythm have been associated with some of the signs
in the autistic spectrum, like seizures or sleep disorders
[23]. Serotonin is a neurotransmitter involved in multiple
aspects of brain functions, ranging from the regulation of
mood to the control of appetite and social interactions
[29] and its production has been reported as deficient in
ASD brains [30]. Tryptophan levels have been demon-
strated to directly influence central nervous system (CNS)
serotonin levels [31] and behavior [32], and altered trypto-
phan transport has been described in fibroblasts from boys
with attention deficit/hyperactivity disorder (ADHD) [33].
It is noteworthy that tryptophan hydroxylase is the rate-
limiting enzyme in the biosynthesis of serotonin and the
gene coding the isoform 2 of this enzyme (TPH2) was
underexpressed in the expression microarray analysis of
lymphoblastoid cells from 10 ASD patients as compared
to controls (P = 0.0166). In the human brain, both
isoforms, TPH1 and TPH2, are ubiquitously expressed
with some particular region-specific differences [34] and
TPH2 expression is significantly higher in the raphe
nuclei, the core of serotonergic system [35]. Thus, lower
expression levels of TPH2 in white cells might reflect
abnormal serotonergic activity in the raphe nuclei. Add-
itionally, the MAOA enzyme in the serotonin pathway
which generates NADH was found to be underexpressed
in cells from ASD patients.
Serotonin also plays a critical role in regulating neur-
onal morphology and circuitry [36] and recent work
showed that placental cells are able to synthesize sero-
tonin from tryptophan provided by the maternal blood
[37]. This exogenous source of serotonin is important in
the neurodevelopment of the forebrain in the first
month of gestation, because the endogenous source
(hindbrain, future serotonergic system) is not sufficient
at this stage. Interestingly, disrupted organization of the
fronto-temporal lobes is one of the most consistentneuroanatomical findings in ASD patients [25], and
lower expression levels of genes involved in synapses,
neurotransmitter transport and neuron projection have
been detected in frontal and temporal lobes of ASD brains
[38]. At the cellular level, such disrupted organization is
reflected by abnormalities in the minicolumns, the basic
functional units of the cortex, which have been reported
in ASD brains to be narrower, increased in number per
cortical area and with reduction of neuropil space, caused
by the smaller size of the peripheral interneurons [25,39].
Conclusions
The data presented in this work indicate that cells from pa-
tients with ASDs, on average, are less capable of utilizing
tryptophan as an energy source than controls. The finding
was consistent in both syndromal and non-syndromal
cases, and was not influenced by age, sex, or genotype of
the patients. We believe that decreased tryptophan metab-
olism in patients with ASDs may alter metabolic pathways
involved in the regulation of the early stages of brain devel-
opment (first month of gestation), mitochondrial homeo-
stasis and immune system activity in the brain. Disruption
of such pathways can primarily be caused either by insuffi-
cient serotonin production by placental cells, mitochondrial
dysfunction and/or impaired balance between quinolinic
and kynurenic acid in fetal cells. The combined effects of
these events could lead to abnormal organization of neu-
rons (minicolumnopathy), particularly in specific brain re-
gions (fronto-temporal lobes, limbic system), determining
the imbalance between the short- and long-term circuitry
that has been considered to be one of the fundamentals of
the ASD neuropathology [25,40]. Pathogenic events involv-
ing one or more branches of such pathways have been de-
scribed. Even though the ideal target tissue, brain, could
not be investigated, our observation of decreased trypto-
phan metabolism in cells from patients with ASDs may
provide a unifying model that could help explain the gen-
etic heterogeneity of ASDs. Our findings perhaps represent
a preliminary step in the development of an array which
could be used to provide a quick and reliable screening test
for ASDs.
Additional files
Additional file 1: Table S1. Genotype and phenotype of the first 17
patients with ASDs tested. Notes. del, deletion; dup, duplication; ID,
intellectual disability; ukn, unknown.
Additional file 2: Table S2. Absorbance data of PM-M1 to M4 plates
for the first 18 controls (C1-C18) and 17 patients with ASDs (A1-A17).
Notes. The data were log-transformed before undergoing statistical
analyses. The wells containing tryptophan are indicated in red. The wells
with P value ≤0.05 are in bold.
Additional file 3: Table S3. Absorbance data of PM-M1 to M4 plates
for the first 18 controls (C1-C18) and 15 patients with different conditions
characterized by ID (N1-N15). Notes. The data were log-transformed
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are indicated in red. The wells with P value <0.05 are in bold.
Additional file 4: Table S4. Significant absorbance data of PM-M4 wells
for 20 controls (C1-C20) and 20 patients with ASDs (A1-A20). Notes. The
data were log-transformed before undergoing statistical analyses. The
wells containing tryptophan are indicated in red.
Additional file 5: Table S5. Expression microarray data for genes
involved in tryptophan metabolic pathways in 10 patients with ASDs
versus 10 controls. Notes. Each cell line from the 10 patients with ASDs
was individually compared to the control group using the Mann–
Whitney one sample test. Bold digits denote that control intensities are
well above detection threshold, red color denotes that the gene is
expressed in the patient significantly more than in controls, blue color
denotes that the gene is expressed in the patient significantly less than
in controls.
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